MULTICENTER PHASE-II STUDY OF BREQUINAR SODIUM IN PATIENTS WITH ADVANCED BREAST-CANCER

In this study, 34 patients with advanced breast cancer were treated wi th brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an a nthracycline-containing regimen. Brequinar was administered intravenou sly at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 17 patients (50%) experiencing grade 3 or 4 toxicity. There were 33 patients evaluable for response: 4 patients (12%; 95% confidence i nterval, 3.4-28.2%) achieved partial responses, 10 patients (30%) were stable, and 19 patients (58%) had progressive disease. We conclude th at. at this dose and schedule, brequinar has only modest activity in p atients with advanced breast cancer.